Mouvex eccentric disc pumps are so efficient and versatile that they are able to pump air even when no fluid is present, which enables them to completely and safely clear both suction and discharge lines during hygienic–pumping processes. (Picture: Mouvex)
Eccentric Disc Pumps

The Bottom-Line Benefits of Product Recovery

The fulcrum in optimizing product yield is the pump that is used to transfer and recover raw materials or finished products through the suction and discharge lines. Learn how eccentric disc pumps feature product-recovery capabilities that significantly reduce waste from hygienic food and beverage, pharmaceutical and cosmetic manufacturing while increasing ROI.

Read on
Turkey – The country between the two seas has linked the orient and occident for centuries and has rich natural and industrial resources. (Picture: Wikimedia Commons)
Pharmaceutical Engineering in Turkey

Qualification and Validation Alla Turca

Turkey is expected to be Europe's next–door emerging market: With its unique position between orient and occident and its focus on progress the country is set for growth. Projects in Turkey's emerging pharmaceutical industry offer great chances but also distinctive challenges – Chemgineering provided qualification and validation support for a Turkish pharmaceutical company in building a new plant for contract manufacturing. Read what two participants from Business and Technology Design experienced there.

Read on
Gert Moelgaard: “Pharmaceutical equipment is in general not made to be flexible. Most of the traditional solutions are not quick to change and clean between products.” (Bild: NNE Pharmaplan)
Gert Moelgaard about Trends in the Pharmaceutical Industry

Why Specialty Medicine Becomes a Challenge to Manufacturing

After the traditional blockbuster era the new blockbusters are specialty medicines — This may change the manufacturing strategy for many pharmaceutical companies and it means new opportunities and challenges for pharmaceutical manufacturing. But today’s technology and equipment require rethinking of the industry to meet the demands of the “new pharma reality”. Who is going to make the pace?

Read on